Meeting
2022 ASCO Annual Meeting
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least first-line therapy: Interim results of a single-arm phase II trial.
Authors
Huaying Wang
Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Huaying Wang , Wenjuan Tian , Yulan Ren , Chuyu Jing , Boer Shan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
ChiCTR2000031932
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5591)
DOI
10.1200/JCO.2022.40.16_suppl.5591
Abstract #
5591
Poster Bd #
467
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.
First Author: Feng Wang
Poster
2023 ASCO Annual Meeting
A multicenter, single-arm, phase 2 study of surufatinib plus toripalimab for patients with advanced endometrial cancer.
First Author: Guangwen Yuan
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Camrelizumab plus apatinib for immunochemotherapy-treated advanced esophageal squamous cell carcinoma: Preliminary results of cohort 2 in CAP 02 study.
First Author: Feng Wang